IBSA expands its product portfolio for the osteoarticular area27 May 2021
Rheumatic diseases are complex chronic medical conditions that affect the joints, bone or muscles. The common denominator of these diseases is that they are characterised by inflammation, pain and swelling, which means that, with time, they have a great impact on the patient’s quality of life.
Osteoarthritis (OA) is a rheumatic disease that affects millions of people in Italy and is currently a major cause of disability. The condition causes gradual wear of the cartilage that protects the bones at joint level, causing pain, stiffness and loss of function. OA is caused by a great many factors and is often associated with aging and excess weight. However, it can also be the result of lesions and injuries, hereditary factors and abuse or lack of exercise.
To find out more, listen to the interview with Prof. Migliore:
As is emphasised by the latest ESCEO* guidelines, prevention is of paramount importance and involves lifestyle intervention and treatment of the osteoarthritis from the very earliest stages. The management and treatment of this condition is not simple and requires a flexible and gradual clinical and therapeutic approach, based on the severity and evolution of the disease, for which the gold-standard treatment is constituted by symptomatic slow-acting drugs of osteoarthritis (SYSADOA), which include substances with a favourable safety profile that are also essential constituents of joint cartilage, such as prescription Chondroitin Sulphate (CS) and Glucosamine.
IBSA has been committed to the osteoarticular area for a long time, with innovative solutions for each stage of the disease’s progression, ranging from oral treatments to products for injection containing Hyaluronic Acid. As a matter of fact, the Company is a world leader in the development of products containing Hyaluronic Acid. With its attention focussed, as always, on patients and their quality of life, IBSA is further expanding its range of treatments with a new practical, once-daily oral formulation containing Chondroitin Sulphate in oral gel form, in order to improve patients’ treatment compliance and adherence.
*European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases